Drugs / CART22-65s
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT03620058 | Sep 2018 → Jan 2036 expected | acute lymphoblastic leukemia | University of Pennsylvania | Active not recruiting | No outcome recorded |
| Phase 1 | NCT02650414 | Jan 2016 → Dec 2037 expected | B-cell acute lymphoblastic leukemia | University of Pennsylvania | Active not recruiting | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT05674175 | Jan 2023 → Jul 2028 expected | B-cell acute lymphoblastic leukemia, lymphoblastic lymphoma | Stephan Grupp MD PhD | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CART22-65s | “0.2-1 x 10\^7 CART22-65s cells/kg as a split dose over three days” NCT02650414 ↗ |
| Modality | Cell therapy | “a novel, fully human anti-CD22/4-1BB CAR T-cell construct, CART22-65s” PMID 40246579 ↗ Apr 2025 |
| Target | CD22 | “We tested a novel, fully human anti-CD22/4-1BB CAR T-cell construct, CART22-65s, in parallel phase I studies for pediatric and adult B-ALL.” PMID 40246579 ↗ Apr 2025 |